#Ep 5: The Consistent Compounders Show :Stay tuned to catch Saurabh Mukherjea in conversation with Sohini Andani, Fund Manager, SBI Mutual Fund.

Glenmark Pharmaceuticals Q4 PAT seen up 30% YoY to Rs. 196.4 cr: Prabhudas Lilladher

Net Sales are expected to increase by 10.8 percent Y-o-Y (down 0.8 percent Q-o-Q) to Rs. 2,490.2 crore, according to Prabhudas Lilladher.

April 12, 2019 / 01:11 PM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Prabhudas Lilladher has come out with its fourth quarter (January-March’ 19) earnings estimates for the Pharma sector. The brokerage house expects Glenmark Pharmaceuticals to report net profit at Rs. 196.4 crore up 30% year-on-year (up 68.8% quarter-on-quarter).


Net Sales are expected to increase by 10.8 percent Y-o-Y (down 0.8 percent Q-o-Q) to Rs. 2,490.2 crore, according to Prabhudas Lilladher.


Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to fall by 2 percent Y-o-Y (down 25.9 percent Q-o-Q) to Rs. 288.7 crore.


Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Moneycontrol News

stay updated

Get Daily News on your Browser
Sections